<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654039</url>
  </required_header>
  <id_info>
    <org_study_id>000385</org_study_id>
    <nct_id>NCT04654039</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)</brief_title>
  <official_title>Post-Marketing Surveillance (PMS) Protocol of REKOVELLE Pre-Filled Pen(Follitropin Delta)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-marketing surveillance study is conducted in accordance with the regulations for&#xD;
      re-examination of domestic new drugs (Standard for Re-Examination of New Drugs: Ministry of&#xD;
      Food and Drug Safety [MFDS]: Notification No. 2017-95, 21 Nov, 2017).&#xD;
&#xD;
      It is important to monitor the pattern of drug use in general practice for a long term after&#xD;
      marketing authorization, and to investigate and identify potential new adverse events (AEs)&#xD;
      and their onset status that were not observed during the drug development phases and any&#xD;
      potential factors that affect safety and effectiveness of the new drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with serious AEs and adverse drug reactions (ADRs)</measure>
    <time_frame>Until the 10 to 11 weeks after the embryo transfer or until the 30 days after treatment termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with unexpected AEs/ADRs not reflected in 'Precautions for Use'</measure>
    <time_frame>Until the 10 to 11 weeks after the embryo transfer or until the 30 days after treatment termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with expected ADRs</measure>
    <time_frame>Until the 10 to 11 weeks after the embryo transfer or until the 30 days after treatment termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with non-serious ADRs</measure>
    <time_frame>Until the 10 to 11 weeks after the embryo transfer or until the 30 days after treatment termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>Until the 10 to 11 weeks after the embryo transfer or until the 30 days after treatment termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical malfunction of REKOVELLE pre-filled pen</measure>
    <time_frame>Until the 10 to 11 weeks after the embryo transfer or until the 30 days after treatment termination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of the oocytes retrieved</measure>
    <time_frame>At the oocyte retrieval visit, after completion of controlled ovarian stimulation and approximately 36 hours after human chorionic gonadotropin (hCG) administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate in women undergoing controlled ovarian stimulation</measure>
    <time_frame>Between 10-11 weeks after embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Treatment of Infertility</arm_group_label>
    <description>Non intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other: Non intervention</intervention_name>
    <description>Non intervention</description>
    <arm_group_label>Treatment of Infertility</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women receiving REKOVELLE pre-filled pen (follitropin delta) within the range of the&#xD;
        approved product labeling in Korea. Patients will be enrolled only after the treatment&#xD;
        decision has been made and no aspect of this study will interfere with or influence the&#xD;
        routine medical procedures and/or medications received.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were prescribed with REKOVELLE (follitropin delta) for the first time&#xD;
             according to the approved administration method and dose&#xD;
&#xD;
          -  Patients who have consented to personal information use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are prohibited from use according to the special warnings and precautions&#xD;
             for use of REKOVELLE (follitropin delta)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centum Eroom Woman Clinic, 10F, Centum Tower Medical, 20, Centum-2-ro, Haeundae-gu</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joymom Infertility Clinic, 359, Jungang-daero, Jung-gu</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Women's Hospital, 7, Munjeong-ro, Seo-gu</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Creation And Love Women's Hospital, 957, Mujin-daero, Seo-gu</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mirae and Heemang Women's Hospital, 7F, Dana Medical Center, 68, Jukbong-daero, Seo-gu</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trinium Woman's Hospital, 1834, MainTower, Hannuridae-ro</name>
      <address>
        <city>Sejong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>M Fertility Center, 12F, 407, Teheran-ro, Gangnam-gu</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mizmedi Hospital, 295, Gangseo-ro, Gangseo-gu</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follitropin Delta</keyword>
  <keyword>REKOVELLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

